Amgen Inc. (AMGN) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Amgen Inc. stock price
Amgen Inc. latest news:
BRIEF-European Commission Approves Amgen, Allergan's Mvasi
Amgen Inc(AMGN): * EUROPEAN COMMISSION APPROVES AMGEN AND ALLERGAN'S MVASI® FOR THE TREATMENT OF CERTAIN TYPES OF CANCER. * Amgen Inc (AMGN) - EUROPEAN COMMISSION HAS GRANTED MARKETING AUTHORIZATION FOR MVASI Source text for Eikon: Further company coverage:
BRIEF-FDA Approves Addition Of Overall Survival Data To Kyprolis Label
Amgen Inc(AMGN): * FDA APPROVES ADDITION OF OVERALL SURVIVAL DATA TO KYPROLIS® LABEL. * Amgen Inc (AMGN) - U.S. FDA APPROVED SUPPLEMENTAL NEW DRUG APPLICATION TO ADD OVERALL SURVIVAL DATA FROM PHASE 3 TRIAL TO PRESCRIBING INFORMATION FOR KYPROLIS Source text for Eikon: Further company coverage:
BRIEF-Amgen says Analysis From Kyprolis Trial Published in Journal Of Clinical Oncology
Amgen Inc(AMGN): * OVERALL SURVIVAL ANALYSIS FROM KYPROLIS® PHASE 3 ASPIRE TRIAL PUBLISHED IN THE JOURNAL OF CLINICAL ONCOLOGY Source text for Eikon: Further company coverage:
Amgen estimates its U.S. tax bill at over $6 billion as it repatriates cash
Amgen Inc(AMGN) said it expects to incur tax expenses of $6 billion to $6.5 billion over time as it repatriates cash it has accumulated around the world because of the new U.S. tax law signed by President Donald Trump on Friday. Some of the expense is also due to the revaluation of its tax liabilities, the drugmaker said in a filing with the Securities and Exchange Commission.
BRIEF-Amgen Announces 15 Percent Increase In Q1 2018 Dividend
Amgen Inc(AMGN): * AMGEN ANNOUNCES 15 PERCENT INCREASE IN 2018 FIRST QUARTER DIVIDEND. * SETS QUARTERLY DIVIDEND OF $1.32PER SHARE Source text for Eikon: Further company coverage:
Amgen raises dividend by 15% to $1.32 a share
Amgen late Tuesday announced that its board of directors declared a dividend of $1.32 a share for the first quarter of 2018. The dividend will be paid on March 8 to stockholders of record as of Feb. 15, the biotech company said. That's a 15% increase from the dividend paid in each of the previous four quarters, Amgen said. Shares of Amgen were flat in late trading after ending the regular session down 0.3%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
UPDATE 1-Amgen's Kyprolis improves overall survival in blood cancer patients
Dec 11 (Reuters) - Amgen Inc said on Monday a final
analysis of late-stage trial data showed that its Kyprolis
combined with two other drugs helped blood cancer patients live
Amgen's Kyprolis improves overall survival in blood cancer patients
Dec 11 (Reuters) - Amgen Inc said on Monday new
data from a late-stage trial testing Kyprolis in combination
with two other drugs showed improved overall survival rate in
patients with blood cancer.
BRIEF-Xencor Receives Milestone Payment From Amgen
Xencor Inc(XNCR): * XENCOR RECEIVES MILESTONE PAYMENT FROM AMGEN. * SAYS IT HAS EARNED A $10 MILLION MILESTONE PAYMENT FROM AMGEN. * SAYS MILESTONE PAYMENT TRIGGERED BY SUBMISSION OF INVESTIGATIONAL NEW DRUG APPLICATION FOR AMG 424. * XENCOR RECEIVES MILESTONE PAYMENT FROM AMGEN Source text for Eikon: Further company coverage:
FDA approves heart protection claims for Amgen cholesterol drug
Dec 1 (Reuters) - Amgen Inc can now promote the
ability of its potent but expensive cholesterol drug to reduce
the risk of heart attacks and strokes, after U.S. health
regulators approved adding those benefits to the medicine's
prescribing label, the company said on Friday.
BRIEF-Amgen Says Aimovig Phase 3 Data Published In The New England Journal Of Medicine Demonstrate Significant, ...
Amgen Inc(AMGN): * AIMOVIG PHASE 3 STRIVE DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE DEMONSTRATE SIGNIFICANT, SUSTAINED EFFICACY IN MIGRAINE PREVENTION Source text for Eikon: Further company coverage:
BRIEF-Amgen Says Aimovig Phase 3 Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention
* AIMOVIG™ (ERENUMAB) PHASE 3 STRIVE DATA PUBLISHED IN THE
ENGLAND JOURNAL OF MEDICINE DEMONSTRATE SIGNIFICANT, SUSTAINED
EFFICACY IN MIGRAINE PREVENTION
Source text for Eikon:
Further company coverage:
Amgen beats EPS, sales revenue, increases guidance
Shares of Amgen Inc. rose 1% late Wednesday after the biotech drug maker reported third-quarter earnings above Wall Street expectations and increased its guidance for the year. Amgen earned $2 billion, or $2.76 a share, in the quarter, compared with $2 billion, or $2.68 a share, in the year-ago period. Adjusted for one-time items, Amgen earned $3.27 a share, up from $3.02 a share a year ago on higher operating margins. Revenue rose fell 1% to $5.77 billion, compared with $5.81 billion a year ago. Analysts polled by FactSet had expected adjusted earnings of $3.11 a share on sales of $5.75 billion. Amgen said hurricane recovery efforts are "well underway" in its Puerto Rico facility with no expected impact on product supply and an expected 2017 impact of 15 cents to 18 cents a share. Amgen revised its 2017 GAAP EPS guidance to between $10.96 and $11.20 a share, and adjusted EPS guidance to between $12.50 and $12.70. The company upped its revenue guidance to between $22.7 billion to $23 billion. The analysts surveyed by FactSet expected adjusted EPS of $12.58 for the year on sales of $22.9 billion. Amgen shares ended the regular trading day down 1.6%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Amgen quarterly profit tops expectations despite sales decline
(Reuters) - Amgen Inc reported higher-than-expected third quarter profit on Wednesday as lower research and other costs and higher operating margins helped offset sales declines in some of its biggest established products.
BRIEF-Amgen's Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS regimen meets primary endpoint
Amgen Inc(AMGN). * Phase 3 A.R.R.O.W. study of once-weekly KYPROLIS regimen meets primary endpoint of progression-free survival in relapsed and refractory multiple myeloma patients. * Amgen Inc(AMGN) - overall safety profile of once-weekly KYPROLIS regimen was comparable to that of twice-weekly regimen Source text for Eikon: Further company coverage:
Amicus Therapeutics, Inc.FOLD
Amkor Technology, Inc.AMKR
Amphastar Pharmaceuticals, Inc.AMPH
Amtech Systems, Inc.ASYS
AmTrust Financial Services, Inc.AFSI
Anacor Pharmaceuticals, Inc.ANAC